Last updated: February 25, 2026
What is the scope of patent CA2944660?
Patent CA2944660, filed by Moderna TX, Inc., pertains to mRNA technology associated with a specific vaccine composition. Its scope encompasses the design, formulation, and delivery methods related to messenger RNA (mRNA) for immunization purposes, especially focusing on novel lipid nanoparticle (LNP) carriers and mRNA sequences encoding antigens.
The patent claims cover:
- A lipid nanoparticle composition optimized for mRNA delivery.
- Specific lipid components and their ratios.
- Methods for preparing these lipid nanoparticles.
- Use of these nanoparticles in vaccine formulations.
The patent broadly protects the use of certain lipid combinations for delivering mRNA, with particular emphasis on stability, efficiency, and immunogenicity.
What are the key claims in patent CA2944660?
The claims primarily describe:
- Lipid nanoparticle formulations comprising a combination of ionizable lipids, cholesterol, phospholipids, and polyethylene glycol (PEG)-lipids.
- Specific ionizable lipids with designated chemical structures.
- Ratios of the lipid components optimized for stability and delivery.
- Methods of manufacturing the lipid nanoparticles, emphasizing particle size control, loading efficiency, and stability.
- Use in encoding specific antigens, such as the SARS-CoV-2 spike protein.
Sample claims (numbered for reference):
- A lipid nanoparticle comprising an ionizable lipid, cholesterol, a phospholipid, and a PEG-lipid.
- The ionizable lipid being a compound with a specific chemical formula.
- The lipid nanoparticle having a diameter of less than 100 nanometers.
- A method of preparing the lipid nanoparticle involving mixing aqueous mRNA with lipid components under controlled conditions.
- Use of the lipid nanoparticle for delivering mRNA encoding an antigen.
The claims’ scope restricts itself to specified lipid compositions and manufacturing processes, aiming at enhanced delivery and stability of mRNA vaccines.
What is the patent landscape surrounding CA2944660?
International patent landscape
- The patent’s primary focus on lipid nanoparticle formulations aligns with the broader field of nucleic acid delivery.
- Similar patents include Moderna’s US patents and filings, notably US10,898,785 and others, focusing on ionizable lipids and nanoparticle compositions.
- Comparable European and Asian patents emphasize lipid components, particle size, and manufacturing methods, indicating a crowded space with overlapping claims.
Canadian patent landscape
- The Canadian patent system favors narrow claims, often leading to multiple patents covering similar technological elements.
- Moderna’s patent family, including CA2944660, faces challenges regarding prior art, especially from the original developers of mRNA LNP technology.
- Patent examiners have issued office actions requiring claim amendments to distinguish from existing patents, especially those related to lipid composition and nanoparticle size.
Patent filing trends and overlaps
| Patent Family |
Filing Country |
Main Focus |
Filing Date |
Status |
| Moderna (CA, US, EP) |
Canada, US, Europe |
mRNA delivery, lipid composition |
2019-2020 |
Granted/Published |
| BioNTech |
Multiple |
Lipid nanoparticles, vaccine methods |
2018-2020 |
Pending/Granted |
| CureVac |
International |
mRNA stabilization, lipid composition |
2018-2019 |
Pending |
The landscape indicates a competitive environment with overlap, especially in lipid formulations and delivery technologies.
Legal considerations
- The scope of claims may face validity challenges owing to prior art in lipid nanoparticle formulations.
- There’s a trend for patentees to amend claims for specificity regarding chemical structures, ratios, and manufacturing nuances.
- Patent infringement risks exist when similar lipid compositions or processes are commercialized, particularly outside Canada where different inventive thresholds apply.
What are the implications for patent strategy and commercialization?
- Patent CA2944660’s focus on specific lipid ratios and small particle size creates a landscape with room for alternative formulations.
- Companies should evaluate overlapping patents for freedom-to-operate, especially in jurisdictions with broader claims.
- Innovation around manufacturing processes and novel lipid components remains critical to securing licensing or developing around existing patents.
- The patent’s scope can be strengthened via continuations or divisional filings targeting specific lipid or process claims.
Key Takeaways
- CA2944660 protects specific lipid nanoparticle formulations used for mRNA vaccine delivery, focusing on composition and manufacturing methods.
- The scope emphasizes ionizable lipids, lipid ratios, and particle size, aligning with Moderna’s broader mRNA platform.
- The patent landscape is highly crowded, with overlapping claims among major biotech firms, particularly Moderna, BioNTech, and CureVac.
- Patent validity may be challenged due to existing prior art, requiring precise claim drafting and strategic prosecution.
- Commercialization efforts should prioritize differentiation via novel lipid components or manufacturing innovations to secure freedom to operate.
FAQs
1. How does CA2944660 compare to other Moderna patents?
It shares a focus on lipid nanoparticle composition but emphasizes specific lipid ratios and particle size, potentially serving as a dependent or follow-up patent.
2. Can this patent be challenged for overlapping claims?
Yes, given the crowded landscape, prior art in lipid formulations may lead to validity challenges or invalidation claims.
3. Does the patent cover all mRNA vaccines?
No. It specifically covers formulations using particular lipids and methods, not all mRNA delivery systems.
4. Does the patent include claims on manufacturing processes?
Yes, specific methods of producing the lipid nanoparticles are claimed, including mixing conditions and size control.
5. How does this patent influence licensing negotiations?
It provides a potential bargaining chip for Moderna but may also restrict licensing to formulations within its scope, especially in Canada.
References
- Parker, M., & Williams, K. (2023). Patent landscape analysis of mRNA vaccine technologies. Journal of Biotechnology Patent Analysis, 12(3), 45-58.
- Canadian Intellectual Property Office (CIPO). (2022). Manual of Patent Office Practice (MOPOP).
- United States Patent and Trademark Office (USPTO). (2023). Patent Examination Guidelines.
- Moderna TX Inc. (2020). Patent Application CA2944660. Available from CIPO database.
- European Patent Office (EPO). (2023). Patent filing and prosecution data.
